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Abstract 
Decisions about prescribed contraception are typically the result of a consultation between a woman 
and her doctor. In order to better understand contraceptive choice within this environment, stated 
preference methods are utilized to ask doctors about what contraceptive options they would discuss 
with different types of women. The role of doctors is to confine their discussion to a subset of 
products that best match their patient. This subset  of options forms the consideration set from 
which the ultimate recommendation is made. Given the existence of consideration sets we address 
the issue of how to model appropriately the ultimate recommendations. The estimated models 
enable us to characterize doctor recommendations and how they vary with patient attributes and to 
highlight where recommendations are clear and when they are uncertain. The results also indicate 
systematic variation in recommendations across different types of doctors and in particular we 
observe that some doctors are reluctant to embrace new products and instead recommend those 
that are more familiar.  Such effects are one possible explanation for the relatively low uptake of 
more cost effective longer acting reversible contraceptives and indicates the need for further 
education and training of doctors may be warranted. 
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1. Introduction  
Maintaining good reproductive health requires women to have access to information about safe, 
effective and affordable methods of contraception. But contraceptive needs differ considerably over 
the reproductive life cycle and the range of contraceptive products available has expanded rapidly 
making it more difficult for women to understand the choices available and the trade-offs they 
present, and for doctors to provide comprehensive information to assist women in making a fully 
informed contraceptive choice.  
 
Our overarching objective is to provide insights into medical decision-making in the case of doctors 
making recommendations about contraceptive products.  The focus on the role of doctors means we 
abstract from some of the elements of the agency relationship that characterize this decision-
making process. It also means that market data on final product choices is not directly applicable. As 
such stated preference (SP) methods are used to ask doctors about what contraceptive options they 
would discuss and ultimately recommend with different types of women. The role of GPs is to use 
their expertise to match women with the appropriate set of products and then to discuss what is 
likely to be a subset of all available products. This is in fact what we observe in the data.  For the 
doctors, their situation is similar to the two-stage decision process mapped out by Manski (1977) 
where an agent first screens all available alternatives, selects a subset of products from the universe 
of total alternatives and then makes their ultimate choice from a subset of the available options that 
forms the consideration set. Various explanations have subsequently been provided for this process 
including exogenous constraints on choices, product awareness, and costs of acquiring and 
processing product information; see Hauser and Wernerfelt (1990), Roberts and Lattin (1991), 
Gilbride and Allenby (2004), Belkar et al. (2006) and Goeree (2008).  
 
Doctors are making a recommendation for a patient rather than a choice for themselves and so 
explanations are different. Doctors are likely to be aware of a wide range of available contraceptive 
products but face a time constraint that may restrict the number of contraception options that they 
will discuss during a consultation with a particular woman.  Moreover, good clinical practice may 
routinely preclude some products for certain women. Despite these differences, we maintain the 
consideration set terminology and draw on the related literature to provide guidance for our 
modelling.        
 
In the SP choice task we ask a sample of Australian general practitioners (GPs) to complete a 
hierarchical sequence of three questions. For a given woman, defined by experimentally 
manipulated socioeconomic and clinical characteristics, GPs were initially asked to decide whether 
they would confine their discussions of contraceptive options according to three broadly defined 
categories of contraceptive products. Then within the broad category they chose, they were asked 
to indicate which specific contraceptive products would form the consideration set to be discussed 
with the patient. Finally, they chose one product that they would recommend as best suited to the 
patient from the consideration set that they had specified in the second question of the choice task.  
 
Because the characteristics of the patients are controlled within the SP environment, our data 
measure how a sample of GPs match recommended products with a patient defined by a mix of 
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predetermined socio-economic and clinical attributes. These data reveal considerable variation in 
recommendations associated with patient characteristics and the econometric analysis is used to 
identify particular types of women where there are extremes in what could be termed clinical 
ambiguity. 
 
The analysis of GP recommendations provides a different perspective on the phenomenon of 
medical practice variation (MPV) that is pervasive across the health sector; see for example 
Wenneberg et al. (1982). Like Davis et al. (2000) and Grytten and Sørensen (2003) the analysis is 
conducted at the physician level in the area of primary care, but they rely on observational data 
where concerns about confounding factors are natural while our controlled SP environment avoids 
these concerns. Our analysis shows that GP characteristics have a substantial role in explaining 
recommendation patterns, lending support to the possibility that MPV is in part driven by 
differences in “styles of practice” that are associated with the GP’s experience, training, expertise 
and receptiveness to new products.  The issue of willingness to embrace new products is especially 
relevant given increasing support for the greater use of more effective longer acting reversible 
contraceptive methods in order to reduce unintended pregnancies and abortion rates; see for 
example Armstrong and Donaldson (2005) and American College of Obstetricians and Gynecologists 
Committee on Gynecologic Practice (2009). 
 
The task of modelling the recommendations, given the existence of consideration sets, raises a 
methodological issue that we need to address. In standard choice modelling situations, the ultimate 
choice is assumed to be made from an exogenously given set of discrete alternatives. That  approach 
would involve modelling our recommendations data using standard choice modelling techniques 
assuming that the particular products initially chosen by the GP form the consideration sets; see for 
example Roberts and Lattin (1991). Carson and Louviere (2006) are warranted in their criticism of 
such an approach. There is a real threat to econometric analysis because it was the doctors who 
indicated which products should form the choice set and hence the assumption of exogeneity 
required by standard choice modelling is potentially problematic. 
 
While there has been considerable research into the motivation of a two-stage decision process: i.e. 
determine a consideration set and then choose from this restricted set, Horowitz and Louviere 
(1995) urge caution about the usefulness of formally modelling the ultimate choice as a two-stage 
process. They argue that a reasonable hypothesis is that the formation of a consideration set is 
simply a reflection of the underlying preferences and hence if these were known there would be no 
extra information to be gained from knowledge of consideration sets. Operationally, information on 
consideration sets will not be useful in predicting final choice given knowledge of preferences. 
 
In our case we proceed along these lines. Our maintained hypothesis is that doctors will choose to 
restrict the number of contraceptive options they discuss and that choice is made on the basis of the 
same factors and associated weights that drive their ultimate recommendation. This approach is 





2. Background to the choice problem  
While market or revealed preference data are available that characterize the contraceptive choices 
different types of women are currently making (Yusuf and Siedlecky (2007) and Gray and McDonald 
(2007)), these data provide little or no detailed information about what is driving these choices. In 
part, this is because the demand for prescribed contraceptive products does not fit the standard 
case of a single decision-maker making choices for themselves. A single decision-maker framework 
would only be appropriate in the extreme cases of a perfectly informed patient making the choice or 
where the doctor makes the choice acting as a perfect agent to maximize the utility of their patient. 
Instead, choice of a contraceptive product can more realistically be characterized as a doctor-patient 
interaction where a better informed doctor makes a recommendation and the woman subsequently 
makes a decision on the basis of her own information and that conveyed by the doctor.  
 
There have been considerable developments in the contraceptive market, leading to the 
introduction of a wider array of oral contraception formulations with new hormonal constituents 
and lower dose formulations as well as new long-acting methods such as hormonal intra-uterine 
devices and implants, injections, dermal patches and vaginal rings. The availability of so many 
different contraceptive choices poses challenges for GPs in providing the balanced and 
comprehensive information necessary for women to be able to make an informed choice. In this 
context it is important to know more about what is driving the recommendations of doctors and 
hence ultimately the decisions of patients given the doctor’s recommendation. 
 
SP methods provide a natural methodology to learn more about this particular choice process. Fiebig 
et al. (2011) note the limited variability in key product characteristics that is observed in market data 
for contraceptives and stress that it is this type of information that is required in order to predict 
how women will respond to new products that constitute different bundles of characteristics. In 
order to address this issue, they develop a discrete choice experiment to estimate woman’s 
preferences for the attributes of different contraceptive products. In a natural extension of this 
work, Knox et al. (2012) investigate discrepancies in the evaluations of contraceptive product 
attributes made by doctors compared to those made by patients.  
 
The SP choice task used here was designed to complement this existing research by focussing on the 
doctor’s recommendation. The task was developed to reflect a typical consultation between a 
woman and her GP in relation to contraception but with a focus on the GP’s decision about what 
products they would recommend. In doing so we abstract from the product attributes and instead 
focus on how the patient characteristics impact on the recommendation of the GP. The underlying 
motivation for this approach is to determine under what circumstances GPs would recommend 






3. Development of the choice task  
The choice task was developed based on findings from a literature review and from focus groups 
conducted with GPs in Australia.  The focus groups were conducted by one of the clinical authors, an 
expert in reproductive health. Specifically, the participants were asked to consider the issues and 
options they would discuss with three hypothetical women, who were chosen to cover a range of 
different life cycle and fertility stages. The three “patients” discussed were a 17 year old who has 
previously only used condoms but is now in a permanent relationship and has come for advice about 
contraception, a 34 year old who has just finished breast feeding, is using the progestogen-only 
(mini-pill) and does not want more children and a 43 year old with 3 children, who wants to avoid 
pregnancy but who has health concerns about the combined pill. GPs indicated what options they 
would discuss with the women, the extent to which they would take their previous contraceptive 
history, likes and dislikes into account, the reasons they would counsel against specific types of 
contraceptives and what personal characteristics and contraceptive attributes they believed were of 
most relevance and importance in each specific situation. Focus group discussions were recorded 
and transcribed, and a thematic analysis was undertaken by two of the authors.   
 
In the choice task, doctors were asked to consider a context where a patient is seeking information, 
advice and possibly a prescription for contraception.  As GPs were considered to be knowledgeable 
about the attributes of contraceptive products on the Australian market, the choice task did not 
specify the product attributes apart from in terms of a label.  Doctors were asked to consider a series 
of hypothetical patient encounters described in terms of the characteristics of the woman (her 
health, her life stage and contraceptive experience and her smoking and socioeconomic status), and 
then to consider which products they would discuss with the woman, and which specific product 
they would recommend. Each woman patient is described by a set of attributes that form the 
experimental design. The final set of attributes and levels are provided in Table 1.  
 
==Table 1 about here== 
 
It is only feasible to show a subset of the (44x36x22) =746,496 possible “women” to the GPs. As we 
wanted to allow for potential interactions between age and fertility plans (each with 4 levels) we 
needed to construct an attribute with 4x4=16 levels. Then the 15 degrees of freedom associated 
with this attribute would correspond to 3 degrees of freedom for the main effects of each of the 
attributes “age” and “fertility plans” and 9 degrees of freedom corresponding to the interaction 
between these two factors. We needed to construct an attribute with 12 levels to estimate the 
interaction between “periods” and “reason for encounter”. Kuhfeld (2006) contains no design with 
two factors, one with 16 levels and one with 12 levels. A standard construction method in this case 
(see for example, Construction 2.3.8 in Street and Burgess (2007)) is to choose one of the factors 
with 4 levels in the design with 64 runs. The whole design is repeated three times but with different 
names for the levels of that one factor in each of the repetitions of the design. So there are 4 levels 
in each of 3 designs giving a factor with 3x4=12 levels in total. Thus, 192 “women” in total are 
divided randomly into 12 versions of 16 women each. The design did not exclude “implausible 




Doctors were asked to answer a sequence of three questions pertaining to each particular patient. A 
stylized version of the choice task providing the three questions and an example illustrating a 
possible sequence of responses is given in Figure 1. The predominant method of contraception 
amongst Australian women is a form of the contraceptive pill. Thus, in Question 1 doctors were 
asked to decide whether they would confine their discussions of contraceptive options according to 
three pre-specified and broadly defined sets of products:  (i) contraceptive pills only; (ii) methods 
other than contraceptive pills; or (iii) contraceptive pills and other methods. Then contingent on the 
broad category they chose, Question 2 required the GP to indicate which specific contraceptive 
products would form the consideration set to be discussed with the patient. The third and final 
question required the GP to choose one product that they would recommend as best suited to the 
patient. Again this third task was contingent on the preceding choice thus potentially constraining 
the alternatives presented to respondents depending on the outcomes of the previous two 
questions and making it impossible for respondents to make inconsistent choices in answering the 
sequence of questions. 
 
===Figure 1 about here=== 
 
The products are identified by labels and, as mentioned above, attributes of products are not 
specified as part of the experiment.  The nine products that were considered are the combined pill, 
the mini-pill, hormonal injection, hormonal implant, hormonal intra-uterine device (hormonal-IUD), 
hormonal patch, vaginal ring, copper IUD device and condoms. Our emphasis was on prescribed 
products but it was thought to be more realistic to include condoms as part of the list of products 
that would likely be discussed, particularly given that doctors may discuss these in addition to a 
prescribed product. The vaginal ring was relatively new to the Australian market and the hormonal 
patch was not available at all.  
 
The choice task was completed on-line. The sample frame for the GPs was a list of 14,816 GPs from 
all states and territories of Australia estimated to be approximately 81% of all recognised GPs 
currently practicing in Australia. The list was randomised and 1,834 GPs were approached by a 
phone call and follow-up fax inviting them to participate in the study. 1,512 responded and 177 
agreed to participate. Because of the low response rate the sample was augmented through 
advertising in GP newsletters and forums and a further 44 GPs volunteered to participate. 162 GPs 
completed the study between December 2008 and June 2009, 22 of whom were volunteers. GP 
participants were offered $A100 remuneration for their time, paid on completion of the choice 
tasks. 
 
As has been found in other studies, the response rate for GPs was low (Britt el al., 2008). We 
therefore compared characteristics of our GP sample to the Australian population of GPs and other 
national samples of GPs, to gauge the representativeness of the sample (Britt el al., 2008). In terms 
of age, location and practice characteristics the sample was representative of Australian GPs. The 
proportion of female GPs however was higher, reflecting the likelihood that this sample was more 




4. Econometric framework 
The econometric analysis proceeds within the framework of a random utility model where the utility 
that doctor i derives from recommending alternative j in choice scenario s is given by 
 
(1)  𝑈𝑖𝑠𝑗 = 𝑋′𝑖𝑠𝛽𝑗 + 𝜀𝑖𝑠𝑗; 𝑖 = 1, ⋯ , 𝑁; 𝑗 = 1, ⋯ , 𝐽; 𝑠 = 1, ⋯ , 𝑆.   
 
The K×1 vector of explanatory variables Xis contains alternative specific constants (ASCs) that here 
represent the different contraceptive products, attributes of the hypothetical women and observed 
characteristics of our sample of GPs. Thus the associated vector of coefficients denoted by  
measure GPs relative valuation of alternative products and how these change with different 
attributes of women and characteristics of GPs. These relative valuations then lead to the resultant 
recommendations. Note that we are not necessarily assuming that GPs are making 
recommendations to maximize the utility of their patients in which case only the attributes of the 
women should matter. The presence of GP effects, conditional on patient characteristics, are 
required in order to capture the differential abilities of GPs to match women with products and 
allows for the possibility that prescribing different products may have different financial implications 
for GPs.  
 
Because of the structure of the data no variables vary over alternatives. The design variables 
depicting different women vary over doctors and scenarios but are context variables that do not 
vary over contraceptive products. Similarly, the characteristics of the doctors will only vary over i 
and not over either j or s. Consequently the associated vector of coefficients does need to vary over 
j. Using (1) and assuming the disturbance terms isj to be identically and independently distributed as 
extreme value, the standard multinomial logit (MNL) specification results.   
 
In the description of the model thus far we have implicitly assumed an exogenously given set of J 
alternatives that does not vary over individuals. In fact having different choice sets being considered 
by different individuals complicates notation but as long as the variation is exogenous it does not 
substantially change the estimation procedures and is routinely accommodated in standard software 
packages such as Stata.    
 
For example, situations where there are a large number of possible options from which to choose 
are easily accommodated in the context of a SP choice task. In related work Fiebig et al. (2011) 
investigated the preferences of women when choosing a contraceptive product from a similar list of 
options to those used here. In that case women were presented with choice sets of three products 
that were chosen as part of the design and so the consideration set is legitimately treated as 
exogenously given. In the current choice task, doctors have been forced to make their final 
recommendation in a structured manner. Doctors actually make a recommendation from the 
alternatives that they have indicated as belonging to the consideration set to be discussed with the 
patient; again see Figure 1 for a particular example of a doctor choosing to recommend the 
hormonal IUD in preference to condoms. Now it is much less obvious that the consideration set can 




Because of the potential problems identified by Horowitz and Louviere (1995) and Carson and 
Louviere (2006) we do not advise conditioning on these consideration sets in estimating models of 
recommendations.  Instead, we follow the argument of Horowitz and Louviere (1995) that a 
consideration set is simply a reflection of the underlying preferences. Implementation of this 
maintained hypothesis requires the estimation of choice models using choice sets comprising the full 
set of contraceptive products ignoring the information on the constrained choice sets available in 
our data. Geweke et al. (2004) is a prominent example where the same approach is used. Once again 
using Figure 1 as an illustrative example, for this particular observation we do not impose the 
consideration set comprising the two products in estimation and instead assume that this doctor is 
making the recommendation as if choosing from the full set of products.  
 
Simplicity of estimation and interpretation are among the main advantages of MNL but these come 
at the cost of some restrictive assumptions that are clearly unrealistic in our choice context. Here we 
adopt the generalized multinomial logit (G-MNL) framework recently developed in Fiebig et al. 
(2010). This includes as a special case the popular mixed logit (MXL) specification; see for example 
Revelt and Train (1998), Brownstone and Train (1999), Hall et al. (2006) and Hole (2008). G-MNL 
provides an appealing and tractable way to extend basic multinomial choice models.  In addition to 
allowing for random parameters which is a natural way to represent preference heterogeneity, G-
MNL allows for individual scale heterogeneity.  The work of Fiebig et al. (2010) highlights the 
empirical importance of accommodating this extra dimension of heterogeneity. Further research by 
Keane and Wasi (2013) demonstrates the flexibility of G-MNL in comparison with latent class 
models. 
 
The full G-MNL model provides flexibility in how scale and taste heterogeneity are combined but can 
involve a large number of parameters especially when there is a large number of alternatives as 
there is here. As such, a relatively parsimonious specification of the G-MNL model is proposed. In the 
current application the structure of our data means it is unlikely that we would be able to estimate 
models including substantial preference heterogeneity given there is no attribute variation over 
alternatives.  The specification chosen to form our base model is given by: 
 
(2)  𝑈𝑖𝑠𝑗 = (𝛼𝑗 + 𝑧
′
𝑖𝛾𝑗 + 𝜂𝑖𝑗) +  𝑋′𝑖𝑠(𝛽𝑗𝜎𝑖) + 𝜀𝑖𝑠𝑗; 𝑖 = 1, ⋯ , 𝑁; 𝑗 = 1, ⋯ , 𝐽; 𝑠 = 1, ⋯ , 𝑆;   
 
where Xis is now interpreted as including only design attributes describing the patients and is 
exclusive of the ASCs representing the different contraceptive products. Heterogeneity in the GP 
valuations of these two distinct sets of variables is treated separately.  Allowing for scale 
heterogeneity, denoted by i , indicates that (2) is observationally equivalent to a particular type of 
preference heterogeneity in the utility weights associated with patient attributes, an observation 
that has led Louviere et al. (2008) to be critical of the standard MXL model. On the other hand the 
ASCs are allowed to vary both deterministically with doctor specific characteristics denoted by zi  
with corresponding weights 𝛾𝑗  and randomly according to an error 𝜂𝑖𝑗 .  It seems appropriate to have 
a more flexible heterogeneity structure for how GPs value products than for how they evaluate the 
attributes of patients. Also, because differential substitution patterns are expected across the 
contraceptive products the ASCs are assumed to be correlated. Specifically the random errors of the 
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ASCs are assumed to have a multivariate normal distribution with zero mean and covariance matrix 
 . Thus the 𝛼𝑗 parameters are the conditional mean valuations of the contraceptive products when 
doctor specific characteristics are set to zero. Assuming random effects to be individual specific 
induces correlation across choice situations, accounting for the dependence structure in unobserved 
utility among the repeated choices of a doctor which comes from the panel structure of the data.  
 
One attraction of a model of scale heterogeneity, as is specified below, is a considerable amount of 
flexibility with the addition of only one parameter. Because i is required to be positive we specify 
an exponential transformation given by: 
 
(3) 𝜎𝑖 = exp(?̅? + 𝜏𝜐𝑖)  
 
where  υi~𝑁(0,1) and ?̅?  is a normalizing constant required to ensure identification of . The 
additional parameter provides a measure of scale heterogeneity. If =0, the G-MNL model reduces 
to a standard MXL specification with random ASCs. Fiebig et al. (2010) argue that ASCs are 
fundamentally different from most observed attributes and as such recommend that they not be 
subject to scaling. 
 
This relatively parsimonious representation of heterogeneity seems reasonable given our particular 
data structure while emphasizing the most important potential sources of heterogeneity. In what 
follows we simply refer to (2) with the associated assumptions as the G-MNL model. The models 
were estimated by maximum simulated likelihood using an extended version of the mixed logit 
procedure developed for Stata by Hole (2007); see Gu et al. (2013) for more detail. 
 
5. Data and summary statistics 
The first two questions in the choice task relate to the existence and composition of consideration 
sets and given our focus in this paper only a very simple descriptive analysis of these data are 
provided.  Answering the first question doctors indicate which of three broad product categories 
they would discuss with a specific patient. The raw frequencies across all 2592 choice occasions 
indicate that doctors will sometimes confine their discussions to “pills only” (3%) or “methods other 
than pills” (22%) but in the vast majority of cases (75%) they consider a mix of “pills and other 
methods”. While this initial stage highlighted the pills/other method distinction, for the second 
question doctors were in fact asked to indicate which particular products they would actually discuss 
and so even those who chose “pills and other methods” in their first question subsequently were 
given the opportunity to indicate a consideration set comprising a subset of products. Over all choice 
occasions, the median and modal number of products discussed (including the condom) is 4 and in 
less than 1% of choice occasions did doctors indicate they would discuss all products. These basic 
results indicate the existence of consideration sets whereby doctors almost always discuss a subset 
of available contraceptive products with patients. 
 
The first column of Table 2 provides the relative frequencies with which each of the products 
appeared in a consideration set, the outcome of Question 2. For comparison, this table also provides 
the relative frequencies of the choices made in the third question, i.e. those products that were 
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ultimately recommended by the doctors. These recommendations are the outcomes that are the 
primary focus of our analysis.    
 
Across all 2592 observations the hormonal patch was rarely considered and was only recommended 
on 0.5% or 13 occasions. This is possibly not surprising given its unavailability in Australia leading to 
unwillingness on the part of doctors to choose this alternative even in a hypothetical setting where 
the product is assumed to be available. In any event, it is difficult to estimate choice models with 
such an infrequently chosen alternative and hence these observations have been dropped in the 
following analyses. (An alternative approach would be to impute a choice from the consideration set 
indicated by doctors. This has not been pursued and is unlikely to lead to big differences in results 
given the small number of observations involved.)  
 
A number of GP characteristics were used in the analyses. They are the doctor’s age, gender, 
whether they were a Fellow of the Royal Australian College of GPs (RACGP), whether they have a 
Family Planning Certificate, whether they graduated from an Australian medical program, whether 
their practice is located in an urban area  and whether they bulk billed implying patients face no out-
of-pocket expenses. Table 3 provides some summary statistics on these key characteristics of the 
doctors in the sample. 
 
==Tables 2 & 3 about here== 
 
6. Estimation results  
6.1 Overview  
The base model given by (2) is estimated using the full set of attributes and with the doctor 
characteristics listed in Table 3 included as interactions with the ASCs. Presenting the estimation 
results efficiently and informatively presents a major challenge.  As previously noted the socio-
demographic characteristics of respondents (the doctors), and the attributes of the women do not 
vary over the alternatives necessitating a specification where their associated coefficients need to 
vary over the alternatives, here the products.  
 
Thus both MNL and G-MNL models involve the estimation of 34 parameters for each of 7 products 
(for identification one set of product parameters is normalized to zero). In our specification of the G-
MNL model there are 29 additional parameters to be estimated. A majority of these additional 
parameters associated with the G-MNL model are individually significantly different from zero at the 
1% level. In particular the parameter that governs the extent of scale heterogeneity is estimated to 
be 0.164, which is relatively small, but is precisely estimated with an asymptotic standard error of 
0.031. Relative to initial MNL estimation there is a dramatic improvement in fit as expected. The 
associated likelihood ratio test statistic is 644.7 with a p< 0.0001. All of this evidence indicates the 
appropriateness of the more flexible G-MNL model that has been estimated.    
 
The full set of estimation results is not presented but is available on request. Instead a range of 
graphical summaries are provided in order to depict the key features of the results. The primary 
approach involves using our estimated G-MNL model to predict product recommendations under a 
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range of different scenarios and then to display the results as boxplots for all eight products.  For 
example, the boxplots in Figure 2 display the prediction results for all sample observations for each 
of the contraceptive products. Thus the distribution of predictions for each product is characterized 
and key summary statistics such as the maximum, minimum, and median predictions can be 
visualized and compared across products.  
 
==Figure 2 about here== 
 
Using Figure 2, the first thing to note is that the median predictions for each of the products are 
similar to the raw sample frequencies of product recommendations reported in Table 2. These do 
not reflect actual contraceptive use across the population of Australian women because our design 
aims to provide a range of different women and for the purposes of estimation will naturally over-
represent women with less common combinations of attributes. But in addition to the central 
tendencies, these predictions provide some key insights related to variation in choices. The 
minimum values indicate there are woman/doctor combinations that will lead to predictions for 
each product being essentially zero. The hormonal implant has the largest minimum prediction of 
only 1.0%. Turning to the maximum values, the combined pill and hormonal IUD stand out. For these 
two products there are woman/doctor combinations where the predicted probability of being 
recommended is approaching unity. Conversely, for the remaining products the predicted 
probability can be very high but still much less than the probabilities of greater than 85% for the 
combined pill and hormonal IUD. The hormonal implant is noteworthy amongst these remaining 
products because it has the highest median predicted probability; as shown in Table 2 it was the 
most frequently recommended product.  
 
6.2 Impact of doctor characteristics 
In an attempt to separate the impact of woman and doctor characteristics, Figure 3 replicates the 
process of producing Figure 2 but this time summarizes predictions for each of the distinct 192 
women produced by the experimental design by averaging over the doctor’s characteristics at each 
of these design points. As expected the range in the predictions has been reduced but in two cases 
these reductions were especially large. For the hormonal injection the maximum prediction has 
dropped from 53% to 30% and for the copper IUD the drop was from 42% to 20%. For these two 
products there is clearly a large doctor effect. 
 
==Figure 3 about here== 
 
The impact of doctor characteristics is further isolated in Figure 4 where the estimated coefficients 
are summarized. Each row provides the estimated coefficients for each of the eight products with 
the combined pill being the base and hence always having a coefficient of zero. In this format it is 
easy to determine contrasts between any pair of products for a given variable by finding the 
difference between the associated product coefficients for the row associated with the particular 
variable. For example, the older the GP the more likely they are to recommend a copper IUD 
compared with the combined pill and even more likely to recommend the IUD over condoms. GPs 
that bulkbill are also more likely to recommend the IUD compared to any other product. Conversely 
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GPs who have a Family Planning Certificate are relatively less likely to recommend the copper IUD 
and relatively more likely to recommend the hormonal IUD. Female GPs, those who are Fellows and 
to a somewhat lesser extent those with a Family Planning Certificate are all associated with being 
relatively more receptive to the new product, the vaginal ring. The same three characteristics are 
also associated with being more inclined to recommend the hormonal IUD. Other large effects are 
that urban GPs are relatively less likely to recommend an IUD or implant but are relatively more 
likely to recommend condoms.   
 
The fact that the normalized combined pill coefficients and the estimated mini-pill coefficients tend 
to be very central for each GP characteristic indicates that these do not play a big role in determining 
the choice of pill products compared to other products. Another way to see this is to refer back to 
Figures 2 and 3 where the distributions for the two pills are not overly sensitive to controlling for 
overall GP effects.          
 
Because the actual estimated coefficients do not easily convert into impacts on probabilities, Figure 
5 illustrates an example of the impact of one of the key GP characteristics. This figure summarizes 
predictions from the estimated G-MNL model where the doctors are separated by whether they 
have a Family Planning Certificate or not. We see that the coefficients that were large in magnitude 
do translate into large impacts on predicted probabilities. Those with Family Planning Certificates 
are much less likely to recommend the injection and copper IUDs and much more likely to 
recommend the vaginal ring, hormonal implant and hormonal IUD.   
 
==Figures 4 & 5 about here== 
 
6.3 Impact of women’s characteristics 
In order to summarize the impact of the women’s characteristics, we seek to answer the following 
questions:  (1) For what type of women are predictions clear? And; (2) for what type of women is 
there considerable uncertainty about what to recommend? As a measure of uncertainty, the 
predicted entropy is calculated for the range of probabilities for each of the distinct 192 women 
defined by the design. As before, we are controlling for doctor effects and concentrating on the 
differences related to the characteristics of the women. The entropy is defined as: 
 





The entropy reaches its minimum of zero when one of the probabilities equals unity while it attains 
its maximum value of log(J)=log(8) when the predicted probabilities follow a uniform distribution. 
Thus by finding the design points associated with the smallest and largest entropy estimates it is 
possible to summarize the characteristics of the associated women.  
 
As expected from Figure 2, the lowest entropy estimates, those that are most certain, are associated 
with women who our model predicts are very likely to be recommended either the combined pill or 
the hormonal IUD. Of the 192 within-sample women, the 29 (15%) observations with the lowest 
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entropy have either of these products with predicted probabilities in excess of 48%. What can we 
say about these women? Amongst these 29 women there were 19 where the large prediction 
coincided with the combined pill and 10 where it was the hormonal IUD. Each of these groups is 
summarized by the boxplots of the predicted probabilities in Figures 6 and 7. 
 
==Figures 6 & 7 about here== 
  
For this first “combined pill” group there are a number of characteristics that matter. The women 
are younger (15 of the 19 are in the two youngest categories meaning they are aged less than 30), 
almost  half are starting prescribed contraception for the first time, most have normal blood 
pressure and none have elevated blood pressure, most have children but are not breastfeeding, only 
one  has problems with compliance and most are non-smokers.  
 
For the second “hormonal IUD” group the women are older (there are none in the youngest 
category), all have problems with periods, only 2 of the 10 have normal blood pressure, 8 of the 10  
have children but are not breastfeeding, most don’t want to have children in the future, most have 
problems with compliance and most are smokers. Consider one particular woman within this group 
whose characteristics include high blood pressure and being a smoker. Good clinical practice dictates 
that a contractive pill is not recommended for this woman and that is what we find. The average 
predicted probability for the combined pill is 0.0007 and for the mini-pill 0.0010. For this woman, 
GPs exhibit a strong preference for the hormonal IUD (average predicted probability of 0.65) after 
essentially eliminating pills. 
 
At the other extreme, maximum entropy occurs when the predicted probability is spread relatively 
evenly across products. For example, the maximum average entropy for any particular woman is 
1.96 and occurs when the predicted probabilities range from 6% for the copper IUD to 19% for the 
hormonal IUD and seven of the eight products have predicted probabilities in excess of 10%. The left 
hand panel of Figure 8 summarizes the predicted probabilities for the 20 women with the highest 
average estimated entropy values. The relatively high predicted probability for the hormonal implant 
in this subset of women is consistent with the earlier observation that this is a popular compromise 
product especially in “difficult” cases. 
 
==Figure 8 about here== 
 
The women associated with the largest entropy values are harder to categorize but of the 20 with 
the largest entropy, only one had normal blood pressure and most planned to have children in the 
next 2 years. This suggests that blood pressure problems and shorter term fertility plans present 
particular challenges for GPs in deciding on a suitable product either because there is no perfect 
match or because there may be several equally good matches. 
 
Note that these results have been averaged over our sample of GPs. It is especially interesting to 
explore how our GPs react to this particular group of difficult women.  The right hand panel of Figure 
8 provides the distributions of predictions over the 268 distinct GP-women observations for this 
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group of 20 women. As in the previous comparison of Figures 2 and 3 the differences in the two 
panels of Figure 8 are attributable to GP effects for this subset of women.     
 
Unlike with the full sample comparison, there are marked differences across all products for this 
group of women. It remains true, that the changes for the hormonal injection and the copper IUD 
are relatively large. But there are also dramatic changes for the implant, hormonal IUD and ring. For 
this group of difficult woman there are relatively large GP effects.  
 
6.4 Diagnostics 
The modelling of recommendations was predicated on an assumption that the formation of a 
consideration set is simply a reflection of underlying preferences. Before proceeding to a discussion 
of the implications of these results we provide some regression diagnostics aimed at indicating 
whether our working hypothesis is reasonable or not.  
 
The working hypothesis implies that no extra information is gained from knowledge of consideration 
sets. Thus in generating the diagnostics we exploit the fact that while modelling recommendations 
was undertaken independently of the consideration set data, this information is available for testing 
purposes and is used in a number of ways.  
 
In addition to the recommendation model that has been estimated ignoring consideration set 
information, consider a second trinomial choice where the outcomes are the initial choice between 
the three broadly defined product groups; “Pill”, “Not Pill” and “All”. Do predictions generated by 
the recommendation model have predictive power in the product group model and vice versa? 
Evidence consistent with our maintained hypothesis requires that recommendation predictions have 
predictive power in the product group regressions but the converse is not true. These diagnostics 
were generated using MNL. This decision was based primarily on computational convenience and 
while we acknowledge that the results could be sensitive to the simplification, there is no a priori 
reason why this should be the case. 
 
In particular, use the recommendation model to generate predictions for all products.  Now 
construct a variable that is the sum of the predictions for the products in the “Not Pill” category and 
include it as an additional covariate in the product group regression. In this estimation, the Wald test 
for the null hypothesis that the additional variable has no explanatory power generates a test 
statistic of 18.23 which when compared to a chi-squared distribution with 2 degrees of freedom 
produces a p=0.0001. Note that this estimation controls for the same attributes and doctor 
characteristics used in the recommendation estimation but even after controlling for these, the 
recommendation predictions have strong explanatory power helping to explain product group 
outcomes.  
 
Reversing the procedure, the product group estimation was used to generate predicted probabilities 
for the “Pill” and “Not Pill” groups. These were then added to the recommendation model to 
produce a Wald test statistic of 9.69 which when compared to a chi-squared distribution with 14 
degrees of freedom produces a p=0.78.  Consistent with our maintained hypothesis, after controlling 
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for the attributes of the women and the characteristics of the doctors, predictions of broad product 
groups have no additional explanatory power in the recommendation model.  
 
For the second type of diagnostic, one might consider formally testing for parameter constancy in 
the recommendation model across the three subsets of observations formed by splitting the sample 
according to which of the three broad product sets that were chosen. However, this is problematic 
because of the very small size of the “Pill” subsample and because our design would potentially be 
seriously compromised leading to the lack of identification of parameters.  
 
Instead a less formal approach is taken and the coefficient estimates and predictions from the full 
recommendations model are compared with those generated for the large “All” subsample The 
simple correlation between the two sets of estimated coefficients is 0.99. Using the two sets of 
results we generate product predictions and isolate the prediction associated with the actual 
recommendation. The correlation of the two sets of predictions across the entire sample is 0.97 and 
even if we restrict attention to the out of sample observations not used in the “All” subsample 
estimation, the correlation is still 0.96. Both sets of estimation results are generating substantively 
similar predictions for the actual recommendations. 
 
7. Discussion of results  
The results presented in Section 6 reveal considerable variation in recommendations associated with 
patient characteristics. This is not totally unexpected within the context of a SP choice task where 
the aim is to provide attributes with levels that encourage respondents to make tradeoffs that result 
in different choices without compromising the external validity of the results by presenting scenarios 
that lack credibility. While there seems to be considerable agreement amongst GPs about who 
should be recommended the combined pill and the hormonal IUD, no such clear agreement emerges 
for the other products. However, the hormonal implant does represent an interesting case. While it 
is recommended on more choice occasions than any other product, it does not reach the levels of 
certainty displayed by the combined pill and the hormonal IUD. One interpretation of this finding is 
that in addition to representing the appropriate contraceptive option for a range of women, the 
implant plays the role of a compromise product in many cases, possibly because of greater 
awareness through marketing; see Windmeijer et al. (2006). Unfortunately we do not have relevant 
GP characteristics that would enable us to test this hypothesis.  
 
On the other hand there are cases where there is considerable variability as to what product to 
recommend even after controlling for differences in GPs. It is possible that for certain types of 
women with complex medical histories there is a range of contraceptive options that GPs view as 
being equally satisfactory. However, the fact that the maximum entropy situation was associated 
with predicted probability spread relatively evenly across all products suggests that this is only a 
partial explanation. We interpret this wide spread of predicted probabilities as evidence of clinical 
ambiguity that derives from uncertainty relating initially to the process of interpreting the women’s 
medical history and then subsequently to the choice of an appropriate contraceptive method; see 
Wolff (1989).  
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While patient characteristics are important in determining what GPs recommend it is also true that 
GP-specific factors also play a role. After controlling for patient characteristics, there is considerable 
variation in recommendation patterns attributable to the GP. Such variation has previously been 
associated with lost opportunities to improve the health of women and to reduce health costs. 
Sonnenberg et al. (2004) estimate the net impact of contraception on women’s health in the US and 
conclude that: 
 
“Increasing the use of more effective methods even modestly at the expense of less 
effective methods will improve health and reduce costs”.  
 
Similarly in a review of sexual health in the UK, Armstrong and Donaldson (2005) used consensus 
methods to derive ideal profiles of contraception provision and compared these with existing 
profiles to conclude that:  
 
“Generally, there is support for a change in the profile of methods supplied, mostly from 
combined hormonal oral methods to longer acting methods and that such a move would 
produce a very large cost saving to the NHS.”  
 
These longer acting methods include the hormonal injection, hormonal implant, hormonal IUD and 
copper IUD. Wellings et al. (2007) explores why the diffusion of long-acting reversible methods has 
been slow in the UK and presents evidence suggesting that it is due to a combination of lack of 
confidence and experience and misconceptions about side-effects. Our results are supportive of the 
Wellings et al. (2007) findings. It is reasonable to assume that GPs who have a Family Planning 
Certificate are better informed about and more experienced prescribing contraception. In our results 
they were more inclined to recommend longer acting methods.  
 
Again if we think in terms of extremes, products rather than patients, the vaginal ring and the 
copper IUD stand out. The vaginal ring is the newest of the contraceptive products considered, 
having been introduced into Australia in 2007. In addition to GPs who have a Family Planning 
Certificate, those who were female and Fellows of the Royal Australian College were very receptive 
to recommending this new product. This is as expected as these characteristics can be viewed as 
measures of quality and engagement in relation to reproductive and sexual health. Also, those 
trained overseas rather than in Australia were more likely to recommend the ring possibly reflecting 
previous experience with the ring in countries where adoption occurred earlier than in Australia. At 
the opposite extreme GPs who have a Family Planning Certificate, were female, Fellows or trained 
overseas were much less likely to recommend the copper IUD which was favoured by older GPs and 
those not in urban practices. The copper IUD has been available for much longer than the hormonal 
IUD and whilst it has valuable attributes, including being hormone-free, it has been largely 
superseded by the newer hormonal device.  This suggests reluctance on the part of some GPs to 
embrace new technologies and instead to rely on more familiar products. Greater investment in the 
education and training of doctors in general practice about the range and relative attributes of 
available contraceptive may be warranted, in particular in relation to the highly effective and cost-
effective long acting reversible methods. 
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Economic incentives whereby health practitioners exploit their position to influence the demand for 
their services has also been suggested as a potential factor that might impact on medical decision-
making and explain medical practice variation; see Davis et al. (2000) and Scott and Shiell (1997). In 
Australia several pill types, including the older combined pill and mini-pill, the hormonal injection, 
hormonal implant and hormonal IUD are available on the Pharmaceutical Benefits Scheme at 
subsidized prices and hence are relatively inexpensive for women. Newer combined pills, the vaginal 
ring and copper IUD are not subsidized. These price differences might impact on GP 
recommendations but would be accounted for by the alternative specific constants. There are no 
other obvious price incentives for GPs that would lead to differential prescribing patterns.  However, 
we do observe a large bulkbilling effect for the copper IUD. As the copper and hormonal IUD are the 
longest lasting of all contraceptives, GPs who bulkbill may be choosing these methods as the most 
cost-effective in the long run for their patients especially for lower income women. This would 
explain the large bulkbilling effect for the copper IUD and is consistent with the positive effect for 
the hormonal IUD. The differential effect between the two IUDs is consistent with the copper IUD 
lasting for up to 10 years compared to 5 years for the hormonal IUD. It could also be related to the 
patient mix associated with practices that bulkbill but we do not have data that would enable us to 
test this. The introduction of financial incentives for GPs could be considered as a means to 
encourage greater use of more effective and cost-effective new technologies, in particular the long 
acting reversible implants and intra-uterine devices. 
The identification of the low entropy, hormonal IUD group of women indicates some support for the 
use of long acting reversible methods. However, these are cases where clear clinical indicators, 
including problems with periods and blood pressure, necessitate a move away from recommending 
contraceptive pills. In the other low entropy case where the clear recommendation was the 
combined pill, there are no clinical reasons why long acting reversible methods shouldn’t be 
recommended. In fact, it could be argued that greater use of longer acting reversible methods will 
be more beneficial for young women in good health and starting prescribed contraception for the 
first time who are potentially at most risk of unintended pregnancy. 
The group of women associated with high entropy is especially interesting. For these women, 
particular combinations of factors make recommendations difficult and GP characteristics drive a 
considerable amount of the variation across and within products. As we have noted there is a 
tendency for GPs who are female, have a Family Planning Certificate and who are Fellows to have 
similar recommendation patterns. In particular, these are typically the most important factors 
determining the recommendation of longer acting reversible methods and these are amongst the 
products that are most impacted by GP characteristics. As we are associating these characteristics 
with GPs being better qualified and engaged with contraception we are again led to suggest the 
need for greater support for education and training in general practice with regard to contraception. 
Notice that the impact on recommendations of a GP being Australian trained does not closely align 
with the estimated impacts of these characteristics. For example, Australian trained GPs were less 
likely to recommend the ring and more likely to recommend the copper IUD. This suggests a gap 





Despite the importance of identifying the impact of contraceptive knowledge and experience of GPs 
on their recommendation choices, we are somewhat limited by our sample size and by the broad 
proxies we are using. It would be especially useful to have more indicators specific to contraception 
and family planning knowledge and to be able to determine how much promotional activities of 
drug companies are influencing Australian GPs. 
    
Evidence has been presented that is broadly supportive of our main hypothesis that when faced with 
a complex choice problem, the GPs in our data have formed consideration sets on the basis of their 
underlying evaluations of all of the contraceptive products being considered for a particular patient.  
The implications of this result are important from a methodological perspective. Even when 
consideration set information is available, choice need not be modelled as a multi-stage process with 
consideration preceding choice. While there may be an efficiency loss associated with this approach, 
under our maintained hypothesis it will not introduce any biases.   
 
In contrast, inappropriate use of consideration set data, ignoring the likely endogeneity of choice 
sets chosen by respondents, will likely lead to biased inferences. Comparing our results with those 
generated when the stated products considered were used to define the choice sets for each choice 
occasion, confirms clear discrepancies between the two sets of estimates. These differences are 
interpreted as a reflection of selection bias as anticipated by Horowitz and Louviere (1995) and 
Carson and Louviere (2006). 
 
For those designing SP choice tasks the current analysis suggests that there may be little to be 
gained by adding extra questions regarding consideration sets if it is the final choice that is of most 
interest. This is not to say that consideration sets are not formed or are unimportant, simply that 
they convey limited additional information about preferences over and above that derived from a 
standard task which simply asks for the preferred choice.   
 
Considerable care needs to be exercised in claiming wide generalisability for our methodological 
results because of the specific nature of the choice problem being considered. In particular, GPs can 
be expected to be relatively well informed about the full range of contraceptive products. Hence all 
contraceptive products presented in the current work can reasonably be expected to belong to the 
universal set of alternatives considered by GPs. In situations where this is not the case there is 
clearly a role for modelling the initial awareness stage as emphasized in Belkar et al. (2006). Also 
non-experts may be more prone to use simplifying heuristics and modelling consideration sets 
becomes more relevant.  
 
8. Conclusions  
By exploiting SP methods we have been able to provide new insights into medical decision-making in 
the particular case of GP recommendations for contraceptives.  These results indicate considerable 
variation in recommendations. In part this is due to patient characteristics which allow us to identify 
particular types of women where there is uncertainty or clinical ambiguity about appropriate 
contraceptives to recommend. But the variation in recommendations is also partly explained by GP 
specific effects or “styles of practice”. In the literature on MPV such effects have been linked to 
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unnecessarily high surgical risks and expenditure levels. Here they provide one credible explanation 
for the relatively low uptake of longer acting reversible contraceptives and hence the source for 
large potential cost savings from reductions in unplanned and unwanted pregnancies. In order to 
capture these savings it may not be enough to incentivise GPs to prescribe longer acting reversible 
contraceptives. Instead it is likely that the first policy response should be to encourage and facilitate 
further education and training of doctors.  
 
Because the contraceptive pill is so entrenched as the default option for many GPs (and women) 
shifting preferences towards long acting reversibles may also require GPs being instructed in how 
this product information is presented to women. Campaigns to educate women on the benefits of 
long acting reversibles may also be warranted. Contraceptive choice is one area where the patient is 
likely to play a considerable role in the prescription choice and given Australian women can freely 
choose their GP, more informed women may gravitate to doctors willing to embrace the new 
technologies.   
 
The results also indicate that in their interactions with patients GPs restrict discussions of 
contraceptive options to form consideration sets. While it is sensible to contemplate other decision-
making models when dealing with complex choice problems, our conclusion is that the assumption 
that both the formation of consideration sets and ultimate choices are governed by the same 
preferences is a reasonable working hypothesis. Moreover, our application to the recommendations 
of contraceptive products by GPs illustrates a viable compromise approach where both 
considerations sets and final choices can be analysed using SP methods.  
 
In further research it would be extremely useful to extend the analysis with a larger sample of GPs 
with more contraceptive-specific detail in order to undertake a more nuanced exploration of GP 
variations. A complementary analysis of women in order to explore their primary sources of 
information on contraception and, when this is sourced from GPs, what they say GPs discuss with 
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Stylised example of a choice task completed by doctors 
FIRST SCREEN 
Woman Attribute Level 
 Age Aged 30-39 years 
 Reason for encounter Starting prescribed contraception for first time 
 Periods No problem with periods 
 Blood pressure Has low blood pressure 
 Relationship In new relationship 
 Children  Has no children 
 Fertility plans Unsure about future fertility plans 
 Pill preference Has no strong opinion about pill 
 Weight concern Is concerned about gaining weight 
 Compliance Has no difficulty with compliance 
 Income  Has a high income 
 Smoking Is a non-smoker 
   
Choice task Question 1  
What would you discuss? 
Options 
(Check one) 
  ○       Pills only 
  ○       Pills and other methods 
  ●       Other methods but not pills 
   
 
SECOND SCREEN 
Choice task Question 2  
Please select the appropriate set 
of products you would discuss? 
Options  
(Check as many as appropriate) 
  ○      Hormonal  injection  
  ○      Hormonal  implant ○      Vaginal ring 
  ●      Hormonal  IUD ○      Copper IUD 
  ○      Hormonal patch ●      Condoms 
    
 
THIRD SCREEN 
Choice task Question 3  
Which ONE of these would you 




  ●     Hormonal  IUD ○       Condoms 
    
* Options displayed on the second screen are conditional on the answer to Question 1. The display is as it would appear given 
the answer was “Other methods but not pills”. Thus the Combined Pill and Mini-pill do not appear on the second screen.  If 
instead the GP answered “Pills only” then only the Combined Pill and Mini-pill would appear.  If the GP answered “Pills and 
other methods” then the full list of products would appear. Similarly the choices for Question 3 answered on the third screen 
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Table 1: Attributes and their levels 
Age  
dagegp 1 Aged 16-19 years 
dagegp2 Aged 20-29 years 
dagegp3 Aged 30-39 years 
dagegp4 Aged 40 years or more 
Reason for encounter  
drfe1 Starting prescribed contraception for first time 
drfe2 Recommencing prescribed contraception 
drfe3 On  pill but dissatisfied  
drfe4 Using non-pill method but dissatisfied  
Periods  
dbleed1 Heavy and/or painful periods 
dbleed 2 Irregular periods 
dbleed 3 No problems with periods 
Blood pressure  
dbp1 Has low blood pressure 
dbp2 Has normal blood pressure 
dbp3x Elevated blood pressure 
Relationship  
drel1 In long-standing relationship 
drel2 In new relationship 
drel3 Has no steady relationship 
drel4 No information about relationship  
Children  
dchild1 Is currently breastfeeding 
dchild2 Has children but is not breast-feeding 
dchild3 Has no children 
Fertility plans  
dfut1 Does not want to have children in future 
dfut2 Plans to have children in next 2 years 
dfut3 Plans to have children but not in next 2 years 
dfut4 Unsure about future fertility plans 
Pill preference  
dpil1 Prefers pill to other methods 
dpil2 Has no strong opinion about pill 
dpil3 Prefers methods other than pill 
Weight  concern  
dwt1 Is concerned about gaining weight   
dwt2 Is not concerned about gaining weight 
Compliance  
dcomp1 Has no difficulty with compliance 
dcomp2 Has difficulty with compliance 
Income  
dpay1 Has a low to middle household income 
dpay2 Has a health care card 
dpay3 Has a high household income 
Smoking    
dsmk1 Is a non-smoker 
dsmk2 Smokes less than 10 cigarettes per day 
dsmk3 Smokes 10 or more cigarettes per day 
Key:  The table shows the dummy variables associated with each level of each attribute. Shaded levels represent those that are omitted for 
estimation and so define a particular base woman. 
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Table 2: Relative frequencies of contraceptive product consideration and recommendation 
Product Considered Recommended 
Combined pill 0.532 0.192 
Mini-pill 0.365 0.076 
Hormonal injection 0.549 0.093 
Hormonal implant 0.746 0.240 
Hormonal IUD 0.564 0.216 
Hormonal patch 0.071 0.005 
Vaginal ring 0.439 0.070 
Copper IUD 0.251 0.043 




Table 3: GP Characteristics* 
Characteristic Mean 
Age (years)  47.0 
Female 0.642 
Fellow RACGP 0.605 
Family Planning Certificate 0.327 
Bulk bill all patients 0.278 
Australian graduate 0.759 
Urban practice 0.778 
* Apart from age, all other variables are binary dummy variables indicating the presence of the characteristic. In the 
econometric models age is standardized by subtracting the mean of 47 and dividing by two standard deviations.  
 
